MCID: PRM038
MIFTS: 44

Primary Agammaglobulinemia

Categories: Blood diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Primary Agammaglobulinemia

Summaries for Primary Agammaglobulinemia

MalaCards based summary : Primary Agammaglobulinemia, also known as antibody deficiency syndrome, is related to immunodeficiency, common variable, 2 and common variable immunodeficiency. An important gene associated with Primary Agammaglobulinemia is TNFRSF13C (TNF Receptor Superfamily Member 13C), and among its related pathways/superpathways are Allograft rejection and TRAF Pathway. The drugs Omeprazole and Propylthiouracil have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and b cells.

Wikipedia : 74 Hypogammaglobulinemia is a problem with the immune system in which not enough gamma globulins are... more...

Related Diseases for Primary Agammaglobulinemia

Diseases in the Agammaglobulinemia family:

Agammaglobulinemia 1, Autosomal Recessive Agammaglobulinemia 6, Autosomal Recessive
Agammaglobulinemia 2, Autosomal Recessive Agammaglobulinemia 3, Autosomal Recessive
Agammaglobulinemia 4, Autosomal Recessive Agammaglobulinemia 5, Autosomal Dominant
Agammaglobulinemia 7, Autosomal Recessive Agammaglobulinemia 8, Autosomal Dominant
Primary Agammaglobulinemia

Diseases related to Primary Agammaglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 4022)
# Related Disease Score Top Affiliating Genes
1 immunodeficiency, common variable, 2 32.5 TNFRSF13C TNFRSF13B
2 common variable immunodeficiency 32.4 TNFRSF13C TNFRSF13B
3 immunoglobulin alpha deficiency 31.6 TNFRSF13C TNFRSF13B
4 cryptococcal meningitis 29.4 TNFRSF13C TNFRSF13B
5 autoimmune disease 29.2 TNFRSF13C TNFRSF13B
6 macroglobulinemia 29.1 TNFRSF13C TNFRSF13B
7 myeloma, multiple 29.1 TNFRSF13C TNFRSF13B
8 b cell deficiency 28.9 TNFRSF13C TNFRSF13B
9 lymphoma, non-hodgkin, familial 28.5 TNFRSF13C TNFRSF13B
10 leukemia, chronic lymphocytic 28.4 TNFRSF13C TNFRSF13B
11 autoinflammation, antibody deficiency, and immune dysregulation, plcg2-associated 12.7
12 specific antibody deficiency 12.7
13 limbic encephalitis with lgi1 antibodies 12.5
14 warm antibody hemolytic anemia 12.5
15 specific antibody deficiency with normal immunoglobulin concentrations and normal numbers of b cells 12.3
16 lymphopenic hypergammaglobulinemia, antibody deficiency, autoimmune hemolytic anemia, and glomerulonephritis 12.3
17 selective immunoglobulin deficiency disease 12.3
18 antiphospholipid syndrome 12.3
19 anti-pit-1 antibody syndrome 12.3
20 familial cold autoinflammatory syndrome 3 12.2
21 other immunodeficiency syndrome with predominantly antibody defects 12.2
22 alopecia antibody deficiency 12.2
23 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 12.2
24 rheumatoid factor-negative juvenile idiopathic arthritis with anti-nuclear antibodies 12.2
25 oligoarticular juvenile idiopathic arthritis with anti-nuclear antibodies 12.2
26 oligoarticular juvenile idiopathic arthritis without anti-nuclear antibodies 12.2
27 limbic encephalitis with dpp6 antibodies 12.2
28 obsolete: limbic encephalitis with ncmags antibodies 12.1
29 limbic encephalitis with nmda receptor antibodies 12.1
30 immunodeficiency, common variable, 1 12.1
31 antigen defined by monoclonal antibody aj9 12.1
32 antigen defined by monoclonal antibody t87 12.1
33 limbic encephalitis associated with antibodies to cell membrane antigens 12.1
34 limbic encephalitis with caspr2 antibodies 12.1
35 polyradiculoneuropathy associated with igg/iga/igm monoclonal gammopathy without known antibodies 12.1
36 limbic encephalitis with neurexin-3 antibodies 12.1
37 response to monoclonal antibody treatment 12.1
38 congenital hypothyroidism due to transplacental passage of tsh-binding inhibitory antibodies 12.1
39 immunodeficiency, common variable, 3 12.1
40 anca-associated vasculitis 12.1
41 goodpasture syndrome 12.0
42 canomad syndrome 12.0
43 cold agglutinin disease 12.0
44 immunodeficiency, common variable, 4 12.0
45 roifman syndrome 12.0
46 immunodeficiency, common variable, 6 12.0
47 immunodeficiency, common variable, 5 11.8
48 myasthenia gravis 11.8
49 thrombotic thrombocytopenic purpura, acquired 11.8
50 hemolytic uremic syndrome, atypical 1 11.6

Graphical network of the top 20 diseases related to Primary Agammaglobulinemia:



Diseases related to Primary Agammaglobulinemia

Symptoms & Phenotypes for Primary Agammaglobulinemia

Drugs & Therapeutics for Primary Agammaglobulinemia

Drugs for Primary Agammaglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1087)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
2
Propylthiouracil Approved, Investigational Phase 4 51-52-5 657298
3 Certoparin Approved, Investigational Phase 4
4
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
5
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
6
Insulin aspart Approved Phase 4 116094-23-6 16132418
7
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
8
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
9
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
10
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
11
Ribavirin Approved Phase 4 36791-04-5 37542
12
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
13
Oritavancin Approved, Investigational Phase 4 171099-57-3 16129632
14
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
15
Penicillin V Approved, Vet_approved Phase 4 87-08-1 6869
16
Methimazole Approved Phase 4 60-56-0 1349907
17
Clarithromycin Approved Phase 4 81103-11-9 84029
18
Insulin detemir Approved Phase 4 169148-63-4 5311023
19
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
20
Sodium citrate Approved, Investigational Phase 4 68-04-2
21
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
22
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
23
Racepinephrine Approved Phase 4 329-65-7 838
24
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
25
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
26
Insulin glargine Approved Phase 4 160337-95-1
27
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
28
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
29
Sorbitol Approved Phase 4 50-70-4 5780
30
Thrombin Approved, Investigational Phase 4
31
Insulin lispro Approved Phase 4 133107-64-9
32
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
33
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
34
Fenofibrate Approved Phase 4 49562-28-9 3339
35
Polyestradiol phosphate Approved Phase 4 28014-46-2
36
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
37
Tibolone Approved, Investigational Phase 4 5630-53-5
38
Drospirenone Approved Phase 4 67392-87-4 68873
39
Methadone Approved Phase 4 76-99-3 4095
40
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
41
Primaquine Approved Phase 4 90-34-6 4908
42
Povidone-iodine Approved Phase 4 25655-41-8
43
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
44
Potassium citrate Approved, Investigational, Vet_approved Phase 4
45
Calcium carbonate Approved, Investigational Phase 4 471-34-1
46
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
47
Pramlintide Approved, Investigational Phase 4 151126-32-8
48
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
49
tannic acid Approved Phase 4 1401-55-4
50
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337

Interventional clinical trials:

(show top 50) (show all 8577)
# Name Status NCT ID Phase Drugs
1 The Polysaccharide Antibody Response Study: Typhim Vi Response and Allohemagglutinins Versus Pneumovax 23 Vaccine Response in the Diagnosis of Specific Polysaccharide Antibody Deficiency Unknown status NCT02429531 Phase 4
2 Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose Unknown status NCT01173302 Phase 4
3 Assessment of Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV Unknown status NCT01954810 Phase 4
4 Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4 rituximab
5 Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab Unknown status NCT00815594 Phase 4 bevacizumab
6 The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
7 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
8 Diagnostic Immunization With Rabies Vaccine in Patients With Primary Immunodeficiency Disorders Unknown status NCT02490956 Phase 4
9 Immunogenicity of Pneumococcal Vaccine in Liver Transplant Recipients Using a Conjugate-Polysaccharide Priming-Booster Strategy Unknown status NCT00152802 Phase 4
10 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
11 Immunogenicity and Safety of 4- vs. 3-standard Doses HBV Vaccination in HIV-infected Adults With Isolated Anti-HBc Antibody Unknown status NCT03212911 Phase 4
12 A Study Comparing the Effectiveness of Two Different Vaccination Schedules of the Combined Hepatitis A and B Vaccine(Twinrix Adult1440/20) Unknown status NCT00216229 Phase 4
13 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
14 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
15 Desensitization With Bortezomib Before a Living Kidney Donation Unknown status NCT01842074 Phase 4 Bortezomib
16 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
17 A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau Unknown status NCT01644721 Phase 4
18 A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau Unknown status NCT01668745 Phase 4
19 Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status. Unknown status NCT02135055 Phase 4 Midazolam;Morphine
20 A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate® Unknown status NCT00262015 Phase 4
21 Comparative Immunogenicity Study of Two Live Attenuated Hepatitis A Vaccines Unknown status NCT03231605 Phase 4
22 Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine Unknown status NCT02146469 Phase 4
23 Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis Unknown status NCT01752335 Phase 4
24 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
25 Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine Unknown status NCT03373669 Phase 4
26 Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults Unknown status NCT01967368 Phase 4 Intanza;Vaxigrip
27 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® Unknown status NCT01553032 Phase 4 Erbitux®
28 Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure Unknown status NCT02569632 Phase 4
29 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
30 Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease Unknown status NCT02792413 Phase 4 Denosumab;NaCl (placebo)
31 Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients Unknown status NCT01512056 Phase 4 AdimFlu-S
32 A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma Unknown status NCT00540930 Phase 4 Ranibizumab
33 A Randomised Controlled Comparison of Campath−Tacrolimus vs IL2R MoAb−Tacrolimus/MMMF in Kidney Transplantation Unknown status NCT00246129 Phase 4 Alemtuzumab;Daclizumab
34 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
35 Research of Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Produced by Immunobiological Technology Institute (Bio-Manguinhos) From Oswaldo Cruz Foundation (Bio-Manguinhos / Fiocruz) Unknown status NCT02648126 Phase 4
36 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
37 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
38 Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients. Unknown status NCT01101750 Phase 4
39 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
40 Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Unknown status NCT02810808 Phase 4 Ranibizumab
41 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
42 Assessing Immunogenicity of Measles-Rubella Vaccine at 6 and 9 Months of Age Unknown status NCT03071575 Phase 4
43 A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
44 L-selenomethionine Supplementation in Children and Adolescents With Autoimmune Thyroiditis: a Randomized Blind Placebo-controlled Clinical Trial Unknown status NCT02644707 Phase 4
45 An Open-Label, Comparative, Randomized, Prospective Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids Unknown status NCT00693446 Phase 4 Sirolimus;Tacrolimus
46 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
47 Safety and Efficacy of Vaccination Against Influenza in Patients With Scleroderma Unknown status NCT01002508 Phase 4
48 The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study Unknown status NCT02771782 Phase 4
49 Immunological Mechanisms of Oralair® (5 Grass Mix Sublingual Allergen Immunotherapy Tablet) in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
50 The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4

Search NIH Clinical Center for Primary Agammaglobulinemia

Genetic Tests for Primary Agammaglobulinemia

Anatomical Context for Primary Agammaglobulinemia

MalaCards organs/tissues related to Primary Agammaglobulinemia:

40
Lung, Breast, B Cells, T Cells, Kidney, Prostate, Testes

Publications for Primary Agammaglobulinemia

Articles related to Primary Agammaglobulinemia:

(show top 50) (show all 339)
# Title Authors PMID Year
1
Recurrent Sinopulmonary Infections in a Patient Whose HIV Masked Common Variable Immunodeficiency. 61
31677106 2019
2
A supramolecular sensor array for selective immunoglobulin deficiency analysis. 61
31495837 2019
3
Outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011-2015. 61
31298691 2019
4
Factors Beyond Lack of Antibody Govern Pulmonary Complications in Primary Antibody Deficiency. 61
31089938 2019
5
Precision health: treating the individual patient with chronic obstructive pulmonary disease. 61
30977152 2019
6
Antioxidant Defense, Redox Homeostasis, and Oxidative Damage in Children With Ataxia Telangiectasia and Nijmegen Breakage Syndrome. 61
31611883 2019
7
Clinical Features and Outcomes of Immunocompromised Children Hospitalized With Laboratory-Confirmed Influenza in the United States, 2011-2015. 61
30358877 2018
8
The effect of omalizumab treatment on IgE and other immunoglobulin levels in patients with chronic spontaneous urticaria and its association with treatment response. 61
30429712 2018
9
Genetic screening of male patients with primary hypogammaglobulinemia can guide diagnosis and clinical management. 61
29709555 2018
10
Vitamin D deficiency in children with recurrent respiratory infections, with or without immunoglobulin deficiency. 61
29128760 2018
11
Limited Innovations After More Than 65 Years of Immunoglobulin Replacement Therapy: Potential of IgA- and IgM-Enriched Formulations to Prevent Bacterial Respiratory Tract Infections. 61
30190722 2018
12
Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma. 61
29032736 2017
13
Nodular Lymphoid Hyperplasia of the Gastrointestinal Tract : a comprehensive review. 61
29560671 2017
14
BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. 61
28530713 2017
15
Mucosal-associated invariant T cells are depleted and functionally altered in patients with common variable immunodeficiency. 61
28011187 2017
16
Terminally differentiated memory T cells are increased in patients with common variable immunodeficiency and selective IgA deficiency. 61
29204088 2017
17
Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma. 61
28056867 2017
18
Clinical and Biological Manifestation of RNF168 Deficiency in Two Polish Siblings. 61
29255463 2017
19
Importance of neonatal immunoglobulin transfer for hippocampal development and behaviour in the newborn pig. 61
28658291 2017
20
Association between common variable immunodeficiency and collagenous infiltrative disorders of the gastrointestinal tract: A series of four patients. 61
27053352 2016
21
Immunoglobulin deficiency in patients with chronic rhinosinusitis: Systematic review of the literature and meta-analysis. 61
26329513 2015
22
Seronegative Celiac Disease and Immunoglobulin Deficiency: Where to Look in the Submerged Iceberg? 61
26371035 2015
23
A novel X-linked trichothiodystrophy associated with a nonsense mutation in RNF113A. 61
25612912 2015
24
[Incidental discovery of an immunoglobulin deficiency]. 61
26027206 2015
25
[Haemophilus influenzae type b meningitis in a vaccinated, immunocompetent infant with reactive arthritis]. 61
25612943 2015
26
Treatment of giardiasis after nonresponse to nitroimidazole. 61
25271363 2014
27
The pleiotropic movement disorders phenotype of adult ataxia-telangiectasia. 61
25122203 2014
28
Education and imaging. Gastrointestinal: Incidentally detected gastric carcinoma in patient with common variable immunoglobulin deficiency. 61
24832778 2014
29
Functional antipolysaccharide immunoglobulin deficiency, recurrent pneumococcal sepsis, and hypergammaglobulinemic purpura. 61
24607051 2014
30
Immunoglobulin deficiency in patients with Streptococcus pneumoniae or Haemophilus influenzae invasive infections. 61
24326288 2014
31
Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). 61
24572654 2014
32
Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. 61
23672995 2013
33
Selective IgA deficiency mimicking Churg-Strauss syndrome and hypereosinophilic syndrome: a case report. 61
23544278 2013
34
Systemic atopy and immunoglobulin deficiency in Turkish patients with vernal keratoconjunctivitis. 61
23323578 2013
35
Utility of blood culture in uncomplicated pneumonia in children. 61
23641172 2013
36
Bronchiolitis obliterans syndrome, hypogammaglobulinemia, and infectious complications of lung transplantation. 61
23260704 2013
37
Immunoglobulin A deficiency in celiac disease. 61
22476042 2012
38
[A genetic systemic disease: clinical description of type 1 myotonic dystrophy in adults]. 61
22572587 2012
39
CNS infections in patients with cancer. 61
22810134 2012
40
Severe atopic dermatitis and transient hypogammaglobulinemia in children. 61
21854413 2012
41
An 18-year-old woman with Kabuki syndrome, immunoglobulin deficiency and granulomatous lymphocytic interstitial lung disease. 61
22372173 2012
42
[Corynebacterium pseudodiphtheriticum causing severe pneumonia in secondary immunoglobulin deficiency]. 61
22109586 2011
43
Accumulation of B1-like B cells in transgenic mice over-expressing catalytically inactive RAG1 in the periphery. 61
22044391 2011
44
Immunoglobulin deficiency in children with Hib vaccine failure. 61
21983357 2011
45
Diffuse duodenal nodular lymphoid hyperplasia: a large cohort of patients etiologically related to Helicobacter pylori infection. 61
21481240 2011
46
Allergic rhinitis and immunoglobulin deficiency in preschool children with frequent upper respiratory illness. 61
21560491 2011
47
B cell depletion for autoimmune diseases in paediatric patients. 61
21120559 2011
48
Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. 61
19889054 2010
49
Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. 61
20173050 2010
50
I.V. immunoglobulin therapy for infectious diseases. 61
20447982 2010

Variations for Primary Agammaglobulinemia

Expression for Primary Agammaglobulinemia

Search GEO for disease gene expression data for Primary Agammaglobulinemia.

Pathways for Primary Agammaglobulinemia

Pathways related to Primary Agammaglobulinemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12 TNFRSF13C TNFRSF13B
2
Show member pathways
11.69 TNFRSF13C TNFRSF13B
3
Show member pathways
11.35 TNFRSF13C TNFRSF13B
4 10.2 TNFRSF13C TNFRSF13B

GO Terms for Primary Agammaglobulinemia

Biological processes related to Primary Agammaglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.16 TNFRSF13C TNFRSF13B
2 adaptive immune response GO:0002250 8.96 TNFRSF13C TNFRSF13B
3 tumor necrosis factor-mediated signaling pathway GO:0033209 8.62 TNFRSF13C TNFRSF13B

Sources for Primary Agammaglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....